Form 4: BiomX Inc. Executive Merav Bassan Reports Acquisition of Restricted Stock Units

Merav Bassan, Chief Development Officer of BiomX Inc., reports the acquisition of 31,749 Restricted Stock Units (RSUs) that are immediately vested and convertible to common stock.

Summary

• Merav Bassan, the Chief Development Officer of BiomX Inc., filed a Form 4 with the SEC.
• The form reports a transaction that occurred on September 16, 2024.
• Bassan acquired 31,749 Restricted Stock Units (RSUs).
• The RSUs are immediately vested and convert into BiomX Inc.'s common stock on a one-for-one basis.
• The price of the RSUs is $0.
• Following the transaction, Bassan directly owns 31,749 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock-based compensation.

Positives

• The immediate vesting of the RSUs suggests confidence in the executive's continued contribution to the company.

Industry Context

Executive compensation through stock grants is a common practice in the biotechnology industry to align management's interests with those of shareholders.

Stakeholder Impact

• The grant of RSUs could have a slightly dilutive effect on existing shareholders.

Key Dates